Nephrology
News
New Methods Found Promising for Predicting CKD Progression
Major Finding: A triple-marker method incorporating serum creatinine, serum cystatin C, and albuminuria levels predicted CKD progression more...
News
Transplant/Nontransplant Outcomes Similar After Endovascular Intervention
Major Finding: Primary, primary-assisted, and secondary patency and limb salvage rates were "essentially the same" in the transplant and...
News
Probiotic Treatment Halves Recurrent UTI Risk
Major Finding: Recurrent culture-confirmed UTI occurred in 7 of 48 women (15%) receiving Lactin-V, compared with 13 of 48 (27%) receiving placebo....
News
ABMS Creates Subspecialty in Female Pelvic Medicine
News
Insoluble Fiber Intake Beneficial for Patients With CKD
Major Finding: Each 10-g/day increase in dietary fiber intake made by patients with chronic kidney disease was associated with a significantly...
News
Study Questions Using Biomarker Targets to Improve CKD Outcomes
Major Finding: Among patients with chronic kidney disease, the risk of death increased 18% for every 1-mg/dL increase in serum phosphorus (...
News
Imaging Recommendations Largely Ignored in Prostate Cancer
Major Finding: More than one-third (39%) of men who were diagnosed with high-risk prostate cancer did not receive the recommended radiographic...
News
Moderate Alcohol Consumption May Be Okay After Renal Transplant
Major Finding: Renal transplant recipients who drank moderate amounts of alcohol were 67% less likely to develop diabetes and 44% less likely to...
News
Pomegranate Extract Produces Mixed Results in Prostate Cancer
Major Finding: Median PSADT increased significantly from 11.9 months to 18.5 months after treatment with pomegranate extract capsules.Data Source...
News
Vandetanib Fails in Metastatic Bladder Cancer
Major Finding: Median progression-free survival was similar at 1.58 months for placebo plus docetaxel and 2.56 months for vandetanib plus...
News
Nab-Paclitaxel Drives Up Response Rate in Metastatic Bladder Cancer
Major Finding: The response rate to second-line nab-paclitaxel was 32%.Data Source: Phase II study in 48 patients with metastatic urothelial...